Harvoni (ledipasvir/sofosbuvir)

Harvoni (ledipasvir / sofosbuvir) is a fixed-dose combination antiviral medication indicated for the treatment of chronic Hepatitis C virus (HCV) infection in adult (and some pediatric) patients infected with genotypes 1, 4, 5 or 6 without cirrhosis or with compensated cirrhosis. European Medicines Agency (EMA) +1 The medication works by combining two mechanisms: sofosbuvir (an NS5B­polymerase inhibitor) prevents the HCV from replicating its RNA, while ledipasvir (an NS5A inhibitor) blocks a different viral protein essential for viral replication and assembly. Drugs.com +1 Typically, treatment is one tablet once daily for 12 weeks, though duration can vary (8–24 weeks) depending on viral genotype, prior treatment history, presence of cirrhosis, or liver transplant status. hepatitiscentral.com Key benefits include: High cure (sustained virologic response) rates of ~94-99% in appropriate patients. European Medicines Agency (EMA) +1 Once-daily dosing, no interferon required in many cases. Fewer side-effects compared to older interferon-based therapies.